The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa
Open accessAbstract
Introduction: Adolescents and young adults aged <25 are a key population in the HIV epidemic, with very high HIV incidence rates in many geographic settings and a large number who have limited access to prevention services. Thus, any biomedical HIV prevention approach should prepare licensure and implementation strategies for young populations. Oral pre‐exposure prophylaxis (PrEP) is the first antiretroviral‐based prevention intervention with proven efficacy across many settings and populations, and regulatory and policy approvals at global and national levels are occurring rapidly. We discuss available data from studies in the United States and South Africa on the use of oral PrEP for HIV prevention in adolescent minors, along with some of the implementation challenges. Discussion: Ongoing studies in the United States and South Africa among youth under the age of 18 should provide the safety data needed by the end of 2016 to contribute to licensure of Truvada as daily PrEP in adolescents. The challenges of completing these studies as well as foreseeable broader challenges highlighted by this work are presented. Adherence to daily PrEP is a greater challenge for younger populations, and poor adherence was associated with decreased efficacy in all PrEP trials. Individual‐level barriers include limited familiarity with antiretroviral‐based prevention, stigma, product storage, and social support. Structural challenges include healthcare financing for PrEP, clinician acceptability and comfort with PrEP delivery, and the limited youth‐friendly health services available. These challenges are discussed in the context of the work done to date in the United States and South Africa, but will likely be magnified in the setting of limited resources in many other countries that are heavily impacted by HIV. Conclusions: Adolescent populations are particularly vulnerable to HIV, and oral PrEP in these populations is likely to have an impact on population‐level HIV incidence. The challenges of disseminating an HIV biomedical prevention tool requiring daily usage in adolescents are formidable, but addressing these issues and starting dialogues will lay the groundwork for the many other HIV prevention tools now being developed and tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that state laws and regulations vary in terms of parental consent requirements for medical services, PrEP implementation in this new population requires different strategies and research that can inform effective delivery [35–37].”
From “Scaling-out” evidence-based interventions to new populations or new health care delivery systems (2017) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Jewkes, R. K., Dunkle, K., Nduna, M., & Shai, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60548-x · Cited by 1,215
Health for the World’s adolescents: A second chance in the second decade
Dick, B., & Ferguson, B. J. (2015) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2014.10.260 · Cited by 959
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Self-citationAdolescent risk taking, impulsivity, and brain development: Implications for prevention
Romer, D. (2010) · Developmental Psychobiology · doi:10.1002/dev.20442 · Cited by 691
Adolescent girls and young women: key populations for HIV epidemic control
Dellar, R. C., Dlamini, S., & Karim, Q. A. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.2.19408 · Cited by 492
The intersection of intimate partner violence against women and HIV/AIDS: a review
Campbell, J. C., Baty, M. L., Ghandour, R. M., Stockman, J. K., Francisco, L. V., & Wagman, J. A. (2008) · International Journal of Injury Control and Safety Promotion · doi:10.1080/17457300802423224 · Cited by 459
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee‐Phillips, T., Brown, E. R., Schwartz, K. D., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 373
Self-citationAn HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S., Rudy, B. J., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rutledge, B. N., Liu, N., Brothers, J., Mulligan, K. M., Zimet, G. D., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 275
Self-citationSullivan, P. S., Rosenberg, E. S., Sanchez, T., Kelley, C. F., Luisi, N., Cooper, H. L. F., DiClemente, R. J., Wingood, G. M., Frew, P. M., Salazar, L. F., et al. (2015) · Annals of Epidemiology · doi:10.1016/j.annepidem.2015.03.006 · Cited by 218
Research works printed but not linked: 6
- HosekS RudyB LandovitzR KapogiannisB SiberryG LiuN et al.An HIV pre‐exposure prophylaxis demonstration project and safety study for young men who have sex with men in the United States (ATN 110).J Int AIDS Soc.2015;18:20479. Available from:http://www.jiasociety.org/index.php/jias/article/view/20479
- GillK MarcusR DietrichJ BennieT HosekS GrayG et al.An analysis of baseline and early data from the Plus Pills study: an open‐label trial of preexposure prophylaxis for South African adolescents. In International AIDS Conference; 2016 July 19; Durban.
- Centers for Disease Control and Prevention., 2014, Clinical guidelines for the use of pre‐exposure prophylaxis to prevent HIV.
- 2015, UNICEF consultation on clinical, ethical and operational onsiderations for the implementation of oral pre‐exposure prophylaxis (PrEP) in sexually active older adolescents (15–19) at high risk of HIV infection: meeting report
- KnopfA OttM LiuN KapogiannisB ZimetG FortenberryD et al.Unexpected benefits and heightened disclosure risks: adolescents’ experiences in a PrEP trial. International AIDS Conference Durban; 2016 July 19.
- BekkerLG HughesJ AmicoR RouxS HendrixC AndersonPL et al.HPTN 067/ADAPT CapeTown:a comparison of daily and nondaily PrEP dosing in African women.Conference on Retroviruses and Opportunistic Infections (CROI) San Francisco CA USA: International AIDS Society;2015Feb 23. p. 23–6.
Cited by
Sorted by citations
“Scaling-out” evidence-based interventions to new populations or new health care delivery systems
Aarons, G. A., Sklar, M., Mustanski, B., Benbow, N., & Brown, C. H. (2017) · Implementation Science · doi:10.1186/s13012-017-0640-6 · Cited by 399
Improving PrEP Implementation Through Multilevel Interventions: A Synthesis of the Literature
Pinto, R. M., Berringer, K. R., Melendez, R. M., & Mmeje, O. O. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2184-4 · Cited by 252
Hosek, S., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rudy, B. J., Rutledge, B. N., Liu, N., Harris, D. R., Mulligan, K. M., Zimet, G. D., et al. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.2007 · Cited by 223
Self-citationSullivan, P. S., Mera, R. M., Mouhanna, F., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., McCallister, S. H., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.009 · Cited by 218
Implementation Research Methodologies for Achieving Scientific Equity and Health Equity
McNulty, M., Smith, J. D., Villamar, J. A., Burnett‐Zeigler, I., Vermeer, W., Benbow, N., Gallo, C. G., Wilensky, U. J., Hjorth, A., Mustanski, B. S., et al. (2019) · Ethnicity & Disease · doi:10.18865/ed.29.s1.83 · Cited by 150
Metadata
- Authors
- Hosek, S., Celum, C., Wilson, C. M., Kapogiannis, B., Delany‐Moretlwe, S., & Bekker, L.
- Affiliations
- John H. Stroger, Jr. Hospital of Cook County (US)
- University of Washington (US)
- University of Alabama at Birmingham (US)
- National Institutes of Health (US)
- University of Cape Town (ZA)
- Corresponding author
- Hosek, Sybil
- Venue
- Journal of the International AIDS Society
- Publisher
- Wiley
- Published
- 2016-10
- Volume
- 19
- Issue
- 7S6
- Pages
- 21107-21107
- ISSN
- 1758-2652 (ISSN-L)
- PMC
- PMC5071778
- OpenAlex
- W2536440088
- Cited by
- 138
- References
- 32
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 19 · 2021: 28 · 2020: 14 · 2019: 19 · 2018: 17 · 2017: 12 · 2016: 2
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the International AIDS Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Adolescent Sexual and Reproductive Health
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- HIV prevention, oral pre-exposure prophylaxis, adolescents, Truvada, PrEP adherence, youth-friendly health services, HIV stigma, health care financing, clinician acceptability, HIV incidence, United States, South Africa
- MeSH terms
- Adolescent, Adult, Delivery of Health Care, Female, Humans, Male, South Africa, United States, HIV Infections, Anti-HIV Agents, Young Adult, Social Stigma, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
